LONG-ACTING ORAL BROMOCRIPTINE (PARLODEL SRO) IN THE TREATMENT OF HYPERPROLACTINEMIA

• Autor(a) principal: Weingrill, Cleide de Oliveira [UNIFESP]
• Data de Publicação: 1992
• Outros Autores: Mussio, Wania [UNIFESP], Moraes, Carlines Rossi Sarno de [UNIFESP], Portes, Evandro de Souza [UNIFESP], Castro, Rita C. [UNIFESP], Lengyel, Ana Maria Judith [UNIFESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://www.fertstert.org/article/S0015-0282(16)54840-7/pdf; http://repositorio.unifesp.br/handle/11600/43680
• topic: PARLODEL SRO; HYPERPROLACTINEMIA

Objectives: To compare the effect of Parlodel SRO (Sandoz, Basel, Switzerland), a long-acting oral bromocriptine, to Parlodel (Sandoz) and to study the chronic effects of Parlodel SRO.Design: The study was twofold: (1) random, double-blind and (2) open.Setting: Patients were studied in an academic environment.Patients: Hyperprolactinemic patients were selected. Sixteen patients were treated during 1 month. Ten patients completed the 1-year follow-up.Interventions: Parlodel SRO or Parlodel was administered during 1 month (first 15 days: 5 mg/d; afterwards: 10 mg/d). Parlodel SRO was given during 1 year in variable doses (maximal 20 mg/d).Main Outcome Measures: Prolactin (PRL) levels, clinical improvement, and side effects were evaluated.Results: After 1 month, 63% of the patients in both groups had normal PRL and 43% had menses. Side effects were similar. After 1 year all patients except one had normal PRL levels, and 89% were ovulating.Conclusions: The efficacy, tolerability, and long duration of action of Parlodel SRO make it an excellent alternative for the treatment of hyperprolactinemic patients.